Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.0070 AUD
Change Today -0.001 / -12.50%
Volume 1.5M
SBN On Other Exchanges
As of 10:14 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

sun biomedical ltd (SBN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/16/15 - A$0.01
52 Week Low
12/29/14 - A$0.0050
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SUN BIOMEDICAL LTD (SBN)

Related News

No related news articles were found.

sun biomedical ltd (SBN) Related Businessweek News

No Related Businessweek News Found

sun biomedical ltd (SBN) Details

Sun Biomedical Limited operates as a biotechnology company in Australia. The company develops and commercializes Oraline, a hand held multi drug test device. It is also developing DMX200, which is in Phase II clinical trials for treating patients with chronic kidney diseases. The company was founded in 2004 and is based in West Perth, Australia.

Founded in 2004

sun biomedical ltd (SBN) Top Compensated Officers

Executive Chairman
Total Annual Compensation: --
Executive Director
Total Annual Compensation: A$54.8K
Compensation as of Fiscal Year 2015.

sun biomedical ltd (SBN) Key Developments

Sun Biomedical Limited Announces Company Earnings Results for the Year Ended June 30, 2015

Sun Biomedical Limited announced company earnings results for the year ended June 30, 2015. For the year, the company reported revenue of AUD 31,423, loss before income tax of AUD 679,539, loss attributable to owners of the company of AUD 679,539 or 0.1706 cents per basic and diluted share, net cash used in operating activities of AUD 547,987, payments for property, plant and equipment of AUD 5,882 compared to the revenue of AUD 40,647, loss before income tax of AUD 527,978, loss attributable to owners of the company of AUD 527,978 or 0.1594 cents per basic and diluted share, net cash used in operating activities of AUD 568,882 for the previous year.

Dimerix Bioscience Receives Human Ethics Committee Approval to Commence Phase II Clinical Trial of DMX200 in Patients with Chronic Kidney Disease

Dimerix Bioscience Limited announced receipt of ethics committee approval under the Clinical Trial Notification scheme of the Australian Therapeutic Goods administration to commence its Phase II clinical trial of DMX200 in patients with Chronic Kidney Disease. Recruitment of patients at the Austin Hospital is expected to commence shortly. The study will investigate the effect of DMX200 on proteinuria in patients with pre existing chronic kidney disease. The DMX200 treatment involves patients who are currently treated with irbesartan, an angiotensin receptor blocker, also taking propagermanium, an anti-inflammatory molecule which acts through the chemokine 2 receptor. The study will be completed under the supervision of Professor David Power, Director of Nephrology at the Austin Hospital, as Principal Investigator. The therapeutic rationale for DMX200 was developed from Dimerix’s core patented technology, known as Receptor – Heteromer Identification Technology (Receptor – HIT) which can be used to elucidate receptor (or drug target) interactions. Applying this technology to receptors such as G-protein coupled receptors (GPCR’s), Dimerix is able to identify differences in signalling behaviour when receptors interact as heteromers, as expected in vivo, compared with the traditional analysis of single target receptors in isolation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBN:AU A$0.01 AUD -0.001

SBN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBN.
View Industry Companies

Industry Analysis


Industry Average

Valuation SBN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUN BIOMEDICAL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at